These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 4741528)

  • 21. [Effect of clofibrate on intracellular enzyme distribution in the rat liver].
    Panchenko LF; Popova SV; Pirozhkov SV; Antonenkov VD
    Tsitologiia; 1983 Nov; 25(11):1302-8. PubMed ID: 6659071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clofibrate hypocholesterolemia associated with increased hepatic copper.
    Klevay LM
    Drug Nutr Interact; 1983; 2(2):131-7. PubMed ID: 6678750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations in rat serum lipids and apolipoproteins following clofibrate treatment.
    Dashti N; Ontko JA
    Atherosclerosis; 1983 Dec; 49(3):255-66. PubMed ID: 6419747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of 11-H-eicosafluoroundecanoic acid on the rat liver-morphological and histometric findings (author's transl)].
    Gohlke R; Schmidt P; David H; Marx I
    Zentralbl Allg Pathol; 1981; 125(6):504-13. PubMed ID: 7331569
    [No Abstract]   [Full Text] [Related]  

  • 25. Accumulation of adipocyte cholesterol during hypolipidemic drug treatment in cholesterol-fed rats.
    Krause BR; Hartman AD
    Biochim Biophys Acta; 1982 Dec; 713(3):485-93. PubMed ID: 7150624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paradoxical effects of clofibrate on liver and muscle metabolism in rats. Induction of myotonia and alteration of fatty acid and glucose oxidation.
    Paul HS; Adibi SA
    J Clin Invest; 1979 Aug; 64(2):405-12. PubMed ID: 457859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Newer hypolipidemic agents.
    Kritchevsky D
    Fed Proc; 1971; 30(3):835-40. PubMed ID: 4996475
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacological profile of BR-931, a new hypolipidemic agent that increases high-density lipoproteins.
    Sirtori CR; Gomarasca P; D'Atri G; Cerutti S; Tronconi G; Scolastico C
    Atherosclerosis; 1978 May; 30(1):45-56. PubMed ID: 209796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparative study of the effects of probucol, fenofibrate and clofibrate on liver ultrastructure in rats (author's transl)].
    Barnard SD; Molello JA; Caldwell WJ; Lebeau JE
    Nouv Presse Med; 1980 Oct; 9(40):3005-7. PubMed ID: 7443440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histopathological image analysis of chemical-induced hepatocellular hypertrophy in mice.
    Asaoka Y; Togashi Y; Mutsuga M; Imura N; Miyoshi T; Miyamoto Y
    Exp Toxicol Pathol; 2016 Apr; 68(4):233-9. PubMed ID: 26776450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of hypolipidemic agents on the hepatic microsomal drug-metabolizing enzyme system of the rat. Induction of cytochrome(s) P-450 with specificity toward terminal hydroxylation of lauric acid.
    Orton TC; Parker GL
    Drug Metab Dispos; 1982; 10(2):110-5. PubMed ID: 6124394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tissue-specific effect of clofibrate on rat lipogenic enzyme gene expression.
    Karbowska J; Kochan Z; Zelewski L; Swierczynski J
    Eur J Pharmacol; 1999 Apr; 370(3):329-36. PubMed ID: 10334510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response of liver and kidney catalase to alpha-p-chlorophenoxyisobutyrate (clofibrate) in C57B1/6J male mice of different ages.
    Baird MB; Zimmerman JA; Massie HR; Samis HV
    Gerontologia; 1974; 20(3):169-78. PubMed ID: 4461328
    [No Abstract]   [Full Text] [Related]  

  • 34. Molecular changes in erythrocyte membranes induced by long-term administration of clofibrate.
    Morales-Aguilera A; Sampayo-Reyes A
    Eur J Pharmacol; 1993 Apr; 245(2):89-95. PubMed ID: 8491258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inducing effect of clofibrate on alkaline phosphatase and histidine-glyoxylate aminotransferase in rat liver.
    Panchenko LF; Popova SV; Antonenkov VD
    Experientia; 1982 Apr; 38(4):433-4. PubMed ID: 7084402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids.
    Parker RA; Kariya T; Grisar JM; Petrow V
    J Med Chem; 1977 Jun; 20(6):781-91. PubMed ID: 406395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of action of hypolipidemic drugs.
    Sirtori CR; Torreggiani D; Fumagalli R
    Adv Exp Med Biol; 1975; 63():123-33. PubMed ID: 1106138
    [No Abstract]   [Full Text] [Related]  

  • 38. Repeated dose liver micronucleus assay using clofibrate in young adult rats.
    Takayanagi T; Takashima R; Wako Y; Kawasako K; Tanaka Y; Hori H; Fujii W
    Mutat Res Genet Toxicol Environ Mutagen; 2015 Mar; 780-781():117-22. PubMed ID: 25892631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of hypolipidaemic drugs on hepatomegaly and micro-bodies in the rat. A new approach to the nature of hepatic peroxisomal proliferation.
    Sim AK; Spencer A; Metz G; Rushton B
    Arzneimittelforschung; 1981; 31(7):1119-26. PubMed ID: 7196761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clofibrate-induced changes in the content of a low molecular-weight polypeptide in rat liver cell cytoplasm].
    Antonenkov VD; Pirozhkov SV; Sal'nikov IaA; Panchenko LF
    Biokhimiia; 1981 Dec; 46(12):2208-14. PubMed ID: 7317540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.